Phillips-Medisize Expands Clinical Manufacturing Capabilities to Serve Growing Drug Delivery Device Market

The company has repurposed its cleanroom to support late stage development of medium- and high-volume products and processes.

This content was submitted directly to this website by the supplier.

Phillips-Medisize’s manufacturing facility in Struer, Denmark will include a dedicated Manufacturing Development and Clinical build unit.
Phillips-Medisize’s manufacturing facility in Struer, Denmark will include a dedicated Manufacturing Development and Clinical build unit.

Phillips-Medisize, a Molex company, announced expansion of its current Global Innovation and Development (GID) site in Struer, Denmark with a dedicated Manufacturing Development and Clinical build unit, which is scheduled to open in the second quarter of 2020.  As a recognized global leader, Phillips-Medisize provides a wide range of custom drug delivery devices, connected health solutions and end-to-end manufacturing services worldwide.

The Phillips-Medisize manufacturing facility will be equipped to serve clients with agile set up for cleanroom assembly and molding (e.g. for clinical trials).  Approximately 500 m2 of floor space from the existing 8400 m2 building will be repurposed for the cleanroom.  The facility is designed to support late stage development of medium- and high-volume products and processes, under GMP and using state-of-the-art equipment. 

“This expansion accelerates the manufacture of innovative, compliant and best-in-class products while reducing time to market and lowering launch risk for drug delivery device customers,” said John Horgan, Vice President, Global Sales and Marketing of Phillips-Medisize.  “Furthermore, it strengthens our client focus in Scandinavia by complementing the activities of our existing GID in Struer and our newest GID in Copenhagen.”

More in Logistics/Distribution